Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension

Elaine Soon, Carmen M Treacy, Mark R Toshner, Robert MacKenzie-Ross, Vijay Manglam, Mark Busbridge, Mark Sinclair-McGarvie, Jayantha Arnold, Karen K Sheares, Nicholas W Morrell, Joanna Pepke-Zaba

ABSTRACT

Background Anaemia is common in left heart failure and is associated with a poorer outcome. Many patients with pulmonary arterial hypertension (PAH) are anaemic or iron-deficient. This study was performed to investigate the prevalence of iron deficiency in PAH and to identify possible causes.

Methods All patients with idiopathic or heritable PAH diagnosed in 1995—2008 were identified. Controls were selected from patients with chronic thromboembolic pulmonary hypertension (CTEPH). Full blood counts were examined and any abnormality was investigated. Patients were excluded if they had a cause for iron deficiency. The prevalence study was based on 85 patients with idiopathic PAH and 120 with CTEPH. A separate group of 20 patients with idiopathic PAH and 24 with CTEPH with matching haemodynamics were prospectively investigated for serum factors affecting iron metabolism.

Results The prevalence study identified a point prevalence of unexplained iron deficiency of 50% in premenopausal women with idiopathic PAH compared with 8% in premenopausal women with CTEPH (p=0.002); 14% in postmenopausal women with idiopathic PAH compared with 6% in postmenopausal women with CTEPH (p=0.16); 28% in men with idiopathic PAH men compared with 2% in men with CTEPH (p=0.002); and 60% in patients with heritable PAH. The serum study showed that patients with idiopathic PAH had lower serum iron and transferrin saturations than those with CTEPH. Interleukin-6 levels correlated with iron levels (r=−0.6, p=0.006) and transferrin saturations (r=−0.68, p=0.001) in idiopathic PAH but not in CTEPH.

Conclusions The prevalence of unexplained iron deficiency is significantly higher in idiopathic PAH than in CTEPH. This may be linked to interleukin-6.

INTRODUCTION

Pulmonary arterial hypertension (PAH) is a group of rare conditions characterised by increased pulmonary artery (PA) pressures and pulmonary vascular resistance which lead to progressive right ventricular failure and death. A range of aetiologies cause PAH, of which congenital heart disease has a well-known association with iron deficiency. This is thought to be the result of right-to-left shunts creating a state of chronic hypoxia. Anaemia and iron deficiency are common in left heart failure and have been shown to be associated with worse symptoms and increased mortality. Iron replacement in these patients improves symptoms and functional capacity.

We have observed high levels of unexplained iron deficiency in our patients with idiopathic PAH, particularly in those with heritable PAH, mainly caused by mutations in the bone morphogenetic protein type 2 receptor (BMPR2). Hepcidin which is the principal hormone governing iron homeostasis, has recently been shown to be critically influenced via a bone morphogenetic protein-dependent pathway. This prompted us to examine formally the prevalence of iron deficiency in idiopathic and heritable PAH and to investigate possible underlying causes. The demonstration of significant iron deficiency in patients with PAH may have important consequences since iron replacement may be expected to improve exercise tolerance and reduce oxidative stress. In addition, iron replacement has been shown to reduce PA pressure in subjects with hypoxic PAH.

METHODS

Subjects

All patients diagnosed with idiopathic and heritable PAH from 1995 to 2008 (n=150) were identified from the database at Papworth Hospital NHS Trust, Cambridge, UK. The definition of idiopathic PAH includes the following: mean PA pressure >25 mm Hg with a pulmonary capillary wedge pressure of <15 mm Hg and no other identifiable cause for PAH being present (Dana Point classification class 1a). Twenty-two patients were excluded on the basis of a pre-existing reason for iron deficiency including gastric ulceration or major surgery (eg, transplant) within a year of developing iron deficiency. Patients with idiopathic PAH with secondary shunts (ie, demonstrable flow via a patent foramen ovale) were included. All patients with distal chronic thromboembolic pulmonary hypertension (CTEPH) and proximal CTEPH who had not undergone pulmonary endarterectomy (n=150), who were diagnosed from 2000 to 2006 and originated from the Papworth catchment area (and therefore accessible for follow-up), were extracted from the database and screened for eligibility as controls. CTEPH was defined as pulmonary hypertension due to the presence of chronic thromboembolism within the pulmonary vasculature (Dana Point classification class 4). Twenty of the 150 patients with CTEPH were excluded because of comorbidities likely to cause iron deficiency or conditions making an accurate assessment of iron status difficult. In all cases the underlying diagnosis was confirmed at

Additional tables are published online only. To view these files please visit the journal online (http://thorax.bmj.com)
a multidisciplinary meeting of experienced physicians, radiologists and surgeons.

Haemodynamics were measured by right heart catheterisation. Values shown were taken from the study nearest the time of diagnosis of iron deficiency (for deficient patients) or the latest right heart catheter. The median time between right heart catheterisation and screening for iron deficiency was 0.8 years (IQR 0–2). We also examined the following factors:

1. the proportion of patients who were formally anticoagulated;
2. the proportion of patients on endothelin receptor antagonists as these drugs have been associated with anaemia; (although this is not thought to be due to blood loss); and
3. the proportion of patients with a baseline oxygen saturation of <95% on air or needing oxygen to maintain saturations of >95%.

**Study design**

The two groups of patients being compared (PAH and CTEPH) were identified retrospectively from the patient database in the Pulmonary Vascular Diseases Unit at Papworth Hospital. Patients with CTEPH were chosen as controls because (1) they suffer from a chronic illness of comparable severity and (2) to lessen the potential confounding effects of anticoagulation, hypoxia and endothelin receptor antagonist use.

Study design

The two groups of patients being compared (PAH and CTEPH) were identified retrospectively from the patient database in the Pulmonary Vascular Diseases Unit at Papworth Hospital. Patients with CTEPH were chosen as controls because (1) they suffer from a chronic illness of comparable severity and (2) to lessen the potential confounding effects of anticoagulation, hypoxia and endothelin receptor antagonist use.
increase in CRP. After two or more attempts at iron screening, these patients were classified as being of indeterminate status and excluded from further analyses.

Patients found to be iron-deficient were referred back to their local hospitals for further investigation. The type of investigation initiated was left to the clinical judgement of the local medical team but included gynaecological, gastroenterological and haematological review as appropriate. All patients with an identifiable cause of iron deficiency were removed. A modified CONSORT diagram is shown in figure 1 to clarify the selection process. The final analysis included a total of 85 patients with PAH and 120 with CTEPH.

A separate group of 20 patients with idiopathic PAH and 24 with CTEPH were sampled prospectively from June to December 2009 for iron indices, hepcidin and interleukin (IL)-6 (the latter being known regulators of iron metabolism). Heparidin was measured using a previously validated immunoassay. The iron status of these patients was previously determined. For every patient with PAH sampled, a patient with CTEPH whose haemodynamic indices were the closest match was chosen as a control from among the inpatients admitted the same week. Four extra patients with CTEPH were included to ensure an equivalent gender distribution.

Analysis and statistics

For the prevalence study, patients were analysed as a whole and also divided into the following groups: (1) premenopausal women; (2) postmenopausal women (defined as 12 consecutive months without having a period); and (3) men.

This was necessary because the prevalence of iron deficiency varies widely between these groups. In the general population, iron deficiency is much more common in premenopausal women due to the demands of menstruation, pregnancy and lactation. Patients with heritable PAH were also analysed as a subset.

Descriptive statistical analyses were carried out on the study population of 85 patients with PAH and 120 CTEPH controls using GraphPad Version 5. Initially the characteristics of all patients with idiopathic PAH and CTEPH were compared as well as the three subgroups. The point prevalence of iron deficiency was then calculated for all patients with idiopathic PAH and CTEPH as well as for the three subgroups. Finally, the characteristics of the iron-deficient and non-deficient patients with idiopathic PAH were compared. Continuous variables are expressed as mean±SD and compared using the Mann–Whitney test (for non-parametric data) and the unpaired t test (for parametric data). Categorical data were compared using the Fisher exact test. Statistical significance was inferred at p<0.05.

Multivariate models were used to analyse the probability of iron deficiency (the response variable) with respect to the following explanatory variables: cause of pulmonary hypertension (ie, IPAH or CTEPH), sex and menopausal status, age, right atrial pressure, mean PA pressure, cardiac index, NYHA class and 6-minute walking distance (6MWD). For all models considered, the model structure was a generalised linear model with logistic link function (see further details in online supplement).

For the serum study the characteristics of the 20 patients with IPAH and 24 with CTEPH were compared. The iron indices, IL-6 and hepcidin levels were then compared using the Wilcoxon rank-sum test for comparison of characteristic means.

### Table 1 Baseline characteristics and haemodynamics of all patients in prevalence study

<table>
<thead>
<tr>
<th>Aetiology/gender</th>
<th>n</th>
<th>Age (years)</th>
<th>RAP (mm Hg)</th>
<th>mPAP (mm Hg)</th>
<th>CI (l/min/m²)</th>
<th>PVR (dyne·cm⁻²)</th>
<th>6MWD (m)</th>
<th>NYHA II/III/IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPAH all</td>
<td>85</td>
<td>51.2 (16.7)*</td>
<td>9.5 (5.4)</td>
<td>52.0 (13.4)*</td>
<td>2.0 (0.6)</td>
<td>981 (462)*</td>
<td>320 (117)*</td>
<td>11/64/10</td>
</tr>
<tr>
<td>CTEPH all</td>
<td>120</td>
<td>60.3 (16.8)</td>
<td>11.1 (6.3)</td>
<td>46.8 (10.5)</td>
<td>2.1 (0.6)</td>
<td>801 (393)</td>
<td>253 (117)</td>
<td>9/63/28</td>
</tr>
<tr>
<td>IPAH premenopausal women</td>
<td>26</td>
<td>37.7 (7.9)</td>
<td>9.2 (5.9)</td>
<td>53.3 (12.0)*</td>
<td>2.0 (0.6)</td>
<td>886 (321)*</td>
<td>342 (99)</td>
<td>4/21/1*</td>
</tr>
<tr>
<td>CTEPH premenopausal women</td>
<td>26</td>
<td>39.0 (11.0)</td>
<td>11.9 (6.6)</td>
<td>45.0 (13.8)</td>
<td>2.3 (0.7)</td>
<td>755 (494)</td>
<td>303 (126)</td>
<td>4/14/8</td>
</tr>
<tr>
<td>IPAH postmenopausal women</td>
<td>34</td>
<td>64.5 (9.5)*</td>
<td>9.8 (5.3)</td>
<td>49.2 (12.5)</td>
<td>2.0 (0.5)</td>
<td>852 (464)</td>
<td>278 (107)*</td>
<td>1/26/7</td>
</tr>
<tr>
<td>CTEPH postmenopausal women</td>
<td>46</td>
<td>69.4 (9.3)</td>
<td>9.5 (5.4)</td>
<td>49.0 (10.2)</td>
<td>2.1 (0.6)</td>
<td>802 (427)</td>
<td>202 (107)</td>
<td>0/29/17</td>
</tr>
<tr>
<td>IPAH men</td>
<td>25</td>
<td>47.3 (18.1)*</td>
<td>9.3 (5.9)</td>
<td>54.5 (15.6)*</td>
<td>2.0 (0.6)</td>
<td>1014 (563)*</td>
<td>343 (138)</td>
<td>6/17/2</td>
</tr>
<tr>
<td>CTEPH men</td>
<td>48</td>
<td>63.9 (14.0)</td>
<td>12.3 (7.0)</td>
<td>46.6 (8.7)</td>
<td>2.1 (0.5)</td>
<td>729 (257)</td>
<td>285 (104)</td>
<td>5/40/3</td>
</tr>
</tbody>
</table>

| *p<0.05 vs corresponding CTEPH group. BMPR2, bone morphogenetic protein receptor type 2; CTEPH, chronic thromboembolic pulmonary hypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance.

### Table 2 Comparison of characteristics which may predispose to iron deficiency

<table>
<thead>
<tr>
<th>Aetiology/gender</th>
<th>Proportion on anticoagulation</th>
<th>Proportion on ERAs</th>
<th>Proportion with saturation &lt;95% on air</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPAH all</td>
<td>67/85 (78.8%)</td>
<td>30/65 (35.3%)</td>
<td>35/65 (41.2%)</td>
</tr>
<tr>
<td>CTEPH all</td>
<td>120/120 (100.0%)</td>
<td>57/120 (47.5%)</td>
<td>60/120 (50.0%)</td>
</tr>
<tr>
<td>p=0.001</td>
<td></td>
<td>p=0.09</td>
<td>p=0.26</td>
</tr>
<tr>
<td>IPAH pre-menopausal women</td>
<td>22/26 (84.6%)</td>
<td>13/26 (50.0%)</td>
<td>9/26 (34.6%)</td>
</tr>
<tr>
<td>CTEPH pre-menopausal women</td>
<td>26/26 (100.0%)</td>
<td>9/26 (34.6%)</td>
<td>7/26 (26.9%)</td>
</tr>
<tr>
<td>p=0.11</td>
<td>p=0.4</td>
<td>p=0.76</td>
<td></td>
</tr>
<tr>
<td>IPAH post-menopausal women</td>
<td>27/34 (79.4%)</td>
<td>8/34 (23.5%)</td>
<td>14/34 (41.2%)</td>
</tr>
<tr>
<td>CTEPH post-menopausal women</td>
<td>46/46 (100.0%)</td>
<td>29/46 (63.0%)</td>
<td>30/46 (65.2%)</td>
</tr>
<tr>
<td>p&lt;0.002</td>
<td>p&lt;0.001</td>
<td>p&lt;0.04</td>
<td></td>
</tr>
<tr>
<td>IPAH men</td>
<td>18/25 (72.0%)</td>
<td>9/25 (36.3%)</td>
<td>12/25 (48.0%)</td>
</tr>
<tr>
<td>CTEPH men</td>
<td>48/48 (100.0%)</td>
<td>19/48 (39.6%)</td>
<td>23/48 (47.9%)</td>
</tr>
<tr>
<td>p&lt;0.001</td>
<td>p=0.80</td>
<td>p=1.0</td>
<td></td>
</tr>
<tr>
<td>IPAH+BMMPR2 mutations</td>
<td>7/10 (70.0%)*</td>
<td>4/10 (40.0%)*</td>
<td>2/10 (20.0%)*</td>
</tr>
</tbody>
</table>

*Unable to calculate a p value as no comparable group of CTEPH patients with BMPR2 mutations. BMPR2, bone morphogenetic protein receptor type 2; CTEPH, chronic thromboembolic pulmonary hypertension; ERA, endothelin receptor antagonist; IPAH, idiopathic pulmonary arterial hypertension.
Mann–Whitney test. Correlations between the iron indices, IL-6 and hepcidin levels were calculated using the Spearman method. Finally, linear regression was used to construct a representative relationship between significantly correlated factors and the relationship derived from patients with idiopathic PAH was compared with that of patients with CTEPH.

**RESULTS**

**Description of PAH and CTEPH groups**

The baseline characteristics and haemodynamics of the PAH and CTEPH groups as a whole and for the subgroups are shown in tables 1 and 2. The patients with PAH were younger than those with CTEPH. There was no significant difference in the right atrial pressures or cardiac indices between any of the IPAH and CTEPH subgroups. Premenopausal IPAH women and men had significantly worse mean PA pressure and pulmonary vascular resistance than their CTEPH counterparts but comparable 6MWD.

The proportion of patients on anticoagulation was higher in patients with CTEPH than in those with PAH. The proportion of patients who had saturations of <95% on air was comparable overall and for the premenopausal women and men subgroups. The proportion of patients on endothelin receptor antagonists was either similar or less in all PAH groups than in the corresponding CTEPH groups. Six of 13 iron-deficient premenopausal women with IPAH either reported menorrhagia or had a record of heavy menstrual loss in their case notes.

**Point prevalence of iron deficiency in PAH and CTEPH groups**

Twenty-six of 85 (30.1%) patients with PAH were iron-deficient compared with 6 of 122 (4.9%) patients with CTEPH (p<0.0001). Thirteen of 26 (50.0%) women with premenopausal idiopathic PAH were iron-deficient with no obvious cause. This was significantly different (p=0.002) from their CTEPH counterparts who had a point prevalence of iron deficiency of 7.7%. A similar pattern was found in the men with idiopathic PAH who had a point prevalence for iron deficiency of 28.0% compared with 2.1% in men with CTEPH (p=0.002). The difference in postmenopausal women was not as marked (14.3% in IPAH vs 6.5% in CTEPH) and this did not reach statistical significance (p=0.16). The highest point prevalence of iron deficiency was found in patients with PAH carrying BMPR2 mutations (6 of 10 patients, 60%). These results are summarised in table 3 and figure 2. For comparison, the prevalence of iron deficiency in the general population is reported to be 7.3–12.3% for premenopausal women, 4.7–8.4% for postmenopausal women and 2.1–3.8% for men.24–25 This analysis included patients with BMPR2 mutations. However, when patients with BMPR2 mutations were excluded, premenopausal women and men with idiopathic PAH still had a higher point prevalence of iron deficiency than those with CTEPH (table 3).

The multivariable model identified the type of pulmonary hypertension and the state of being a premenopausal woman as having the most impact on the presence or absence of iron deficiency. If all other explanatory variables were held fixed, changing the cause of pulmonary hypertension from CTEPH to idiopathic PAH increases the risk of being deficient in iron by 52.9%. Being a premenopausal woman increases the risk of being iron-deficient by 24.0% if all other variables are held fixed at the middle of their ranges.

Twenty-three of 32 (72%) of the iron-deficient patients were anaemic compared with 6 of 151 (4%) non-deficient patients. Patients with iron deficiency had a mean haemoglobin of 10.4±1.0 g/dl (normal range 13.0–18.0 g/dl for men and 11.5–16.5 g/dl for women), an average mean corpuscular volume of 77.2±11.0 fl (normal range 77.0–95.0 fl) and a mean corpuscular haemoglobin concentration of 25.8±5.9 g/dl (normal range 27.0–32.0 g/dl).

**Comparison of iron-deficient and iron-replete patients with PAH**

The iron-deficient patients were younger than the iron-replete patients (46±15 vs 55±16 years, p=0.02). There were no differences between groups in right atrial pressures, cardiac indices, FVR, 6MWD or the proportion of patients who were hypoxic, antinuclear antibody-positive or treated with endothelin receptor antagonists (table 4). There was a trend towards a higher mean PA pressure in the iron-deficient patients but this did not reach significance (56±11 vs 50±14 mm Hg, p=0.06).

**Iron indices and humoral factors in PAH versus CTEPH**

To investigate the basis of the unexplained iron deficiency in patients with PAH, we measured iron indices and humoral factors known to influence iron metabolism (ie, hepcidin and IL-6)19–22 in a population of 20 patients with idiopathic PAH...
and 24 with CTEPH. As the patients with CTEPH were chosen to match the haemodynamic indices of those with PAH, there were no significant differences in right atrial pressure, mean PA pressure or cardiac index between these two groups (full details in table 2 in online supplement). The idiopathic PAH group tended to be iron-deficient when compared with the CTEPH group, with a lower serum iron (15.5±6.3 vs 23.0±11.0 µmol/l, p=0.02) and lower transferrin saturation (25.9±8.9 vs 37.4±14.8%, p=0.008). The hepcidin level in idiopathic PAH was lower but this did not quite reach statistical significance (25.1±18.8 vs 39.7±27.6 ng/ml, p=0.07). IL-6 levels were similar in both IPAH and CTEPH (4.3±3.5 vs 4.2±2.8 pg/ml, p=0.99). Full results are shown in figure 3.

Interestingly, the relationship between IL-6 and iron metabolism may be different in PAH and CTEPH. There was a significant correlation between iron levels and IL-6 values in idiopathic PAH (r=−0.6, p=0.006) but not in CTEPH (r=−0.36, p=0.09). Similarly, there was a correlation between iron levels and transferrin saturations in PAH (r=−0.68, p=0.001) but not in CTEPH (r=−0.25, p=0.27). When this is plotted graphically, it becomes apparent that in general, for a given value of IL-6, the corresponding iron value and transferrin saturation is lower in the PAH group than in the CTEPH group (figure 4). IL-6 is generally thought to act on iron metabolism via hepcidin, which negatively regulates iron absorption and recycling.20–22 However, higher IL-6 levels are associated with increased hepcidin in CTEPH but not in PAH (figure 4).

**DISCUSSION**

This is the first study to demonstrate an association between iron deficiency and idiopathic PAH. This is particularly marked in premenopausal women and patients with heritable PAH harbouring BMPR2 mutations. Iron deficiency is well recognised in patients with PAH secondary to congenital heart disease.1,2 This is usually associated with polycythaemia and the underlying mechanism is thought to be hypoxia-driven secondary erythropoiesis. Anaemia is also common in left heart failure.5,6 There are several theories as to why this might be the case. First there is an inflammatory milieu associated with heart failure, and increased levels of cytokines such as IL-6 could drive an ‘anaemia of chronic inflammation’.26 Chronic left heart failure is also associated with a general dysfunction of both myelopoietic and erythropoietic lineages, with both reduced colony-forming potential and increased apoptosis.27 Haematologic deficiencies including B12, folate and iron deficiencies have also been detected in 6%, 8% and 15%, respectively, of a group of anaemic patients with left heart failure.6 It is also possible that advanced heart failure leads to generalised gut oedema which prevents iron absorption.

We considered possible explanations for iron deficiency in our patients. The proportion of patients with saturations <95% on air was comparable in the PAH and CTEPH groups (41% vs 50%, p=0.26) while patients in the PAH group were iron-deficient to a greater degree. We also compared haemodynamic indices between iron-deficient and iron-replete patients since advanced right heart failure might lead to gut oedema and iron malabsorption. However, there was no difference in right atrial pressures or cardiac indices between these two groups.

An inflammatory basis for the iron deficiency and anaemia in PAH seems likely as it has previously been demonstrated that patients with PAH have increased levels of IL-6.28 Indeed, we have shown that IL-6 levels predict mortality in these patients.29

**Figure 3** Iron indices and humoral factors affecting iron metabolism in matched IPAH and CTEPH patients. CTEPH, chronic thromboembolic pulmonary hypertension; IL-6, interleukin-6; IPAH, idiopathic pulmonary arterial hypertension; %TSAT, % transferrin saturation; UIBC, unsaturated iron binding capacity.

**Table 4** Comparison of parameters between iron-deficient and iron-replete patients with IPAH

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Iron-deficient</th>
<th>Iron-replete</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>26</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>45.5 (15.4)</td>
<td>55.2 (16.1)</td>
<td>0.02</td>
</tr>
<tr>
<td>RAP, mm Hg</td>
<td>9.5 (5.0)</td>
<td>9.5 (5.6)</td>
<td>0.95</td>
</tr>
<tr>
<td>Mean PA pressure, mm Hg</td>
<td>55.9 (11.2)</td>
<td>50.3 (14.0)</td>
<td>0.06</td>
</tr>
<tr>
<td>CI, l/m²</td>
<td>2.1 (0.6)</td>
<td>1.9 (0.6)</td>
<td>0.39</td>
</tr>
<tr>
<td>Pulmonary vascular resistance, dynes.cm⁻¹</td>
<td>939 (408)</td>
<td>1000 (448)</td>
<td>0.55</td>
</tr>
<tr>
<td>6MWD, m</td>
<td>320 (122)</td>
<td>320 (119)</td>
<td>0.97</td>
</tr>
<tr>
<td>Proportion ANA-positive</td>
<td>3/26 (11.5%)</td>
<td>11/59 (18.8%)</td>
<td>0.54</td>
</tr>
<tr>
<td>Proportion with saturation &lt;95% on room air</td>
<td>12/26 (46.2%)</td>
<td>23/59 (40.0%)</td>
<td>0.79</td>
</tr>
<tr>
<td>Proportion treated with ERAs</td>
<td>13/26 (50.0%)</td>
<td>17/59 (28.8%)</td>
<td>0.09</td>
</tr>
</tbody>
</table>

ANA, antinuclear antibody; CI, cardiac index; ERA, endothelin receptor antagonist; IPAH, idiopathic pulmonary arterial hypertension; 6MWD, 6-minute walking distance; PA, pulmonary artery; RAP, right atrial pressure.
IL-6 can stimulate production of hepcidin, the principal hormone governing iron homeostasis, in vitro and in vivo. We have shown that, for a given value of IL-6, the corresponding iron value is lower in the PAH group than in the CTEPH group. However, higher IL-6 levels are associated with increased hepcidin in CTEPH but not in PAH. This leads us to postulate that the effect of IL-6 is uncoupled from hepcidin regulation in PAH compared with CTEPH, either due to an increased sensitivity on the part of the PAH patients or that IL-6 is acting via a different mechanism. Hepcidin has recently been shown to act via a BMP-dependent pathway. The fact that patients with BMP2R mutations have the highest point prevalence of iron deficiency might suggest an interaction between the loss of BMP2R function, IL-6 and iron metabolism.

The principal limitation of the prevalence study lies in its retrospective design. As a result, there was no set protocol for investigating iron deficiency and the onus was on the referring medical teams to investigate underlying causes. Finally, iron deficiency may have a previously unrecognised impact on the symptoms and prognosis of these patients. The French respiratory home care network, the Association Nationale pour le Traitement à Domicile de l’Insuffisance Respiratoire Chronique, has shown an association between low haemoglobin levels and mortality in patients with chronic obstructive pulmonary disease. Anemia is also shown to be associated with increased hospitalisation rates and worse mortality rates in patients with left heart failure. A Cochrane review covering erythropoiesis-stimulating agents in 794 patients with chronic heart failure has shown lower mortality and better exercise tolerance with no increase in adverse events in the treatment groups. Recently, Krasuski et al have demonstrated a link between anaemia and poorer survival in a group of patients with pulmonary hypertension of mixed aetiologies. Our study highlights the prevalence of iron deficiency in PAH, and it would seem prudent to recommend screening for iron deficiency in these patients. It remains to be determined what the optimal method of iron replacement will be in these patients and whether such an intervention would significantly impact on symptoms or survival.

CONCLUSIONS

The prevalence of iron deficiency is significantly higher in patients with idiopathic and heritable PAH than in a comparable group of patients with CTEPH. This is not attributable to warfarin or endothelin receptor antagonist use and may be linked to IL-6. Further investigation is needed to elucidate the mechanism of iron deficiency in these patients and to determine whether iron supplementation will be beneficial.

Acknowledgements Ms Denise Hodgkins was responsible for setting up the patient database. Ms Natalie Doughty assisted in data collection.

Funding This work was partly funded by an MRC (UK) (to ES) Research Training Fellowship, the British Heart Foundation, the Cambridge NIHR Biomedical Research Centre and the Sackler studentship.

Competing interests ES has received travel grants from Encysive and GlaxoSmithKline and an unrelated unrestricted research grant from Pfizer. CMT has received travel grants from Actelion. MRT has received travel grants from Encysive and GlaxoSmithKline. KKS has received honoraria from Encysive Pharmaceuticals for an advisory board meeting and travel grants from Actelion, United Therapeutics Corporation, Encysive and GlaxoSmithKline. KKS has received honoraria for educational talks from Actelion and Pfizer and a research grant from Novartis. JP-Z has received honoraria from Actelion, Pfizer, GlaxoSmithKline, Encysive and Schering for speaking at conferences and advisory board meetings. She also holds a joint grant of £75K between Actelion, Pfizer, Schering and United Therapeutics. VM, MB and JA have no competing interests.

Ethics approval This study was conducted with the approval of the Cambridgeshire 3 Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Lung alert

The inhibition of anaplastic lymphoma kinase in non-small cell lung tumours with the ALK rearrangement may result in tumour shrinkage

In this study, the therapeutic efficacy of inhibiting anaplastic lymphoma kinase (ALK) in oncogenic fusion genes consisting of EML4 and ALK was explored in an early-phase clinical trial of crizotinib. Tumour samples from 1500 patients with non-small cell lung cancer (NSCLC) were screened for the presence of ALK rearrangements and 82 patients with advanced ALK positive disease were identified. They were started on crizotinib 250 mg twice daily in 28-day cycles.

Results showed that patients with ALK rearrangements were younger than those without the rearrangements and most patients had little or no exposure to tobacco.

At the mean treatment duration of 6.4 months, the overall response rate was 57% and 33% had stable disease. A total of 63 of the 82 patients continued to receive crizotinib at the time of data cut-off, and the estimated probability of a 6-month progression-free survival was 72%.

The inhibition of ALK in lung tumours with the ALK rearrangement resulted in tumour shrinkage or stable disease in most patients, providing a case for genotyping in lung cancer. However, this arrangement is only seen in 5% of NSCLC.


Louise Hancock

Correspondence to Dr Louise Hancock, North Middlesex Hospital, London, UK, lhancock@doctors.org.uk

Published Online First 10 February 2011

Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension

Elaine Soon, Carmen M Treacy, Mark R Toshner, Robert MacKenzie-Ross, Vijay Manglam, Mark Busbridge, Mark Sinclair-McGarvie, Jayantha Arnold, Karen K Sheares, Nicholas W Morrell and Joanna Pepke-Zaba

Thorax 2011 66: 326-332 originally published online February 5, 2011
doi: 10.1136/thx.2010.147272

Updated information and services can be found at:
http://thorax.bmj.com/content/66/4/326

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2011/02/04/thx.2010.147272.DC2
http://thorax.bmj.com/content/suppl/2011/01/11/thx.2010.147272.DC1

References
This article cites 28 articles, 7 of which you can access for free at:
http://thorax.bmj.com/content/66/4/326#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Epidemiologic studies (1829)
Pulmonary hypertension (205)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/